{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:00:38Z","timestamp":1757779238991},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T00:00:00Z","timestamp":1266969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00392-010-0129-7","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T22:19:22Z","timestamp":1266963562000},"page":"369-373","source":"Crossref","is-referenced-by-count":10,"title":["Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study"],"prefix":"10.1007","volume":"99","author":[{"given":"Fikret","family":"Er","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evren","family":"Caglayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natig","family":"Gassanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir M.","family":"Nia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erland","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,24]]},"reference":[{"issue":"23","key":"129_CR1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"DG Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825\u20131833","journal-title":"N Engl J Med"},{"issue":"10","key":"129_CR2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0002-9149(99)80655-9","volume":"75","author":"KD Donovan","year":"1995","unstructured":"Donovan KD, Power BM, Hockings BE, Dobb GJ, Lee KY (1995) Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 75(10):693\u2013697","journal-title":"Am J Cardiol"},{"issue":"5","key":"129_CR3","doi-asserted-by":"crossref","first-page":"50A","DOI":"10.1016\/0002-9149(92)91078-I","volume":"70","author":"KD Donovan","year":"1992","unstructured":"Donovan KD, Dobb GJ, Coombs LJ, Lee KY, Weekes JN, Murdock CJ, Clarke GM (1992) Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 70(5):50A\u201354A (discussion 54A-55A)","journal-title":"Am J Cardiol"},{"issue":"9","key":"129_CR4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0002-9149(00)01128-0","volume":"86","author":"FJ Martinez-Marcos","year":"2000","unstructured":"Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos JM, Camacho C (2000) Comparison of intravenous flecainide, propafenone. and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 86(9):950\u2013953","journal-title":"Am J Cardiol"},{"issue":"23","key":"129_CR5","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","volume":"351","author":"P Alboni","year":"2004","unstructured":"Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggioli G (2004) Outpatient treatment of recent-onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach. N Engl J Med 351(23):2384\u20132391","journal-title":"N Engl J Med"},{"issue":"17","key":"129_CR6","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0002-9149(91)90308-8","volume":"68","author":"T Akiyama","year":"1991","unstructured":"Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA (1991) Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investig Am J Cardiol 68(17):1551\u20131555","journal-title":"CAST Investig Am J Cardiol"},{"issue":"12","key":"129_CR7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","volume":"324","author":"DS Echt","year":"1991","unstructured":"Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324(12):781\u2013788","journal-title":"N Engl J Med"},{"issue":"4","key":"129_CR8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","volume":"327","author":"Cardiac Arrhythmia Suppression Trial II Investigators","year":"1992","unstructured":"Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327(4):227\u2013233","journal-title":"N Engl J Med"},{"issue":"13","key":"129_CR9","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.1993.03510130095038","volume":"270","author":"KK Teo","year":"1993","unstructured":"Teo KK, Yusuf S, Furberg CD (1993) Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270(13):1589\u20131595","journal-title":"JAMA"},{"issue":"3","key":"129_CR10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/hc0302.102575","volume":"105","author":"G Assmann","year":"2002","unstructured":"Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105(3):310\u2013315","journal-title":"Circulation"},{"issue":"9342","key":"129_CR11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(02)11315-8","volume":"360","author":"P Kirchhof","year":"2002","unstructured":"Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Bocker D, Breithardt G, Haverkamp W, Borggrefe M (2002) Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 360(9342):1275\u20131279","journal-title":"Lancet"},{"issue":"23","key":"129_CR12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","volume":"347","author":"IC Gelder Van","year":"2002","unstructured":"Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23):1834\u20131840","journal-title":"N Engl J Med"},{"issue":"9244","key":"129_CR13","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","volume":"356","author":"SH Hohnloser","year":"2000","unstructured":"Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation\u2013Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244):1789\u20131794","journal-title":"Lancet"},{"issue":"10","key":"129_CR14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","volume":"41","author":"J Carlsson","year":"2003","unstructured":"Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41(10):1690\u20131696","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"129_CR15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1378\/chest.126.2.476","volume":"126","author":"G Opolski","year":"2004","unstructured":"Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126(2):476\u2013486","journal-title":"Chest"},{"issue":"2","key":"129_CR16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00392-007-0584-y","volume":"97","author":"T Becker","year":"2008","unstructured":"Becker T, Kleemann T, Strauss M, Doenges K, Schneider S, Senges J, Seidl K (2008) Long-term prognosis after cardioversion of the first episode of symptomatic atrial fibrillation: a condition believed to be benign revised. Clin Res Cardiol 97(2):74\u201382","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"129_CR17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00392-006-0466-8","volume":"96","author":"T Kleemann","year":"2007","unstructured":"Kleemann T, Becker T, Donges K, Vater M, Gut B, Schneider S, Senges J, Seidl K (2007) The prognostic impact of successful cardioversion of atrial fibrillation in patients with organic heart disease. Clin Res Cardiol 96(2):103\u2013108","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"129_CR18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0002-9149(94)90915-6","volume":"74","author":"A Capucci","year":"1994","unstructured":"Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, Della Casa S, Binetti N, Cavazza M et al (1994) Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74(5):503\u2013505","journal-title":"Am J Cardiol"},{"issue":"17","key":"129_CR19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0002-9149(88)90282-2","volume":"62","author":"HJ Crijns","year":"1988","unstructured":"Crijns HJ, van Gelder IC, Lie KI (1988) Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 62(17):1303\u20131306","journal-title":"Am J Cardiol"},{"issue":"1","key":"129_CR20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/heart.84.1.37","volume":"84","author":"NJ Alp","year":"2000","unstructured":"Alp NJ, Bell JA, Shahi M (2000) Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation. Heart 84(1):37\u201340","journal-title":"Heart"},{"issue":"6 Suppl","key":"129_CR21","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.hrthm.2008.02.025","volume":"5","author":"S Iravanian","year":"2008","unstructured":"Iravanian S, Dudley SC Jr (2008) The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5(6 Suppl):S12\u2013S17","journal-title":"Heart Rhythm"},{"issue":"1","key":"129_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1592\/phco.29.1.31","volume":"29","author":"KM Makkar","year":"2009","unstructured":"Makkar KM, Sanoski CA, Spinler SA (2009) Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 29(1):31\u201348","journal-title":"Pharmacotherapy"},{"issue":"5","key":"129_CR23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/eurheartj\/ehi668","volume":"27","author":"JR Ehrlich","year":"2006","unstructured":"Ehrlich JR, Hohnloser SH, Nattel S (2006) Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27(5):512\u2013518","journal-title":"Eur Heart J"},{"issue":"1","key":"129_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacc.2008.08.071","volume":"53","author":"F Belluzzi","year":"2009","unstructured":"Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S (2009) Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53(1):24\u201329","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"129_CR25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.hrthm.2004.08.008","volume":"1","author":"KT Murray","year":"2004","unstructured":"Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, Solomon AJ, Olgin JE, Wilson MJ, Dimarco JP, Beckman KJ, Dennish G, Naccarelli GV, Ray WA (2004) Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 1(6):669\u2013675","journal-title":"Heart Rhythm"},{"issue":"3","key":"129_CR26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1540-8159.2004.00444.x","volume":"27","author":"VE Climent","year":"2004","unstructured":"Climent VE, Marin F, Mainar L, Gomez-Aldaravi R, Martinez JG, Chorro FJ, Roman P, Sogorb F (2004) Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 27(3):368\u2013372","journal-title":"Pacing Clin Electrophysiol"},{"issue":"7","key":"129_CR27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","volume":"360","author":"SH Hohnloser","year":"2009","unstructured":"Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360(7):668\u2013678","journal-title":"N Engl J Med"},{"issue":"12","key":"129_CR28","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","volume":"117","author":"D Roy","year":"2008","unstructured":"Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ (2008) Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117(12):1518\u20131525","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-010-0129-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-010-0129-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-010-0129-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:21:58Z","timestamp":1559060518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-010-0129-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,24]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1007\/s00392-010-0129-7","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,24]]}}}